156118-16-0

Basic information

• Product Name: 2-BROMO-5-AMINO-4-PICOLINE
• Synonyms: 2-BROMO-5-AMINO-4-PICOLINE;5-Amino-2-bromo-4-methylpyridine;3-Amino-6-bromo-4-methylpyridine;3-Pyridinamine, 6-bromo-4-methyl-;6-Bromo-4-methyl-3-pyridinamine;6-BroMo-4-Methyl-pyridin-3-ylaMine;2-BROMO-5-AMINO-4-PICOLIN...
• CAS NO: 156118-16-0
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.03718
• Product Categories: Pyridine;Boronic Acid;Amino-pyridine series;Heterocycle-Pyridine series
• Mol File: 156118-16-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 306.9 °C at 760 mmHg
• Flash Point: 139.4 °C
• Appearance: Brown/Powder
• Density: 1.593 g/cm³
• Vapor Pressure: 0.000752mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 2.38±0.18(Predicted)
• CAS DataBase Reference: 2-BROMO-5-AMINO-4-PICOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-5-AMINO-4-PICOLINE(156118-16-0)
• EPA Substance Registry System: 2-BROMO-5-AMINO-4-PICOLINE(156118-16-0)

Safety Data

• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 156118-16-0(Hazardous Substances Data)

Usage

General Description

2-Bromo-5-amino-4-picoline is a chemical compound with the molecular formula C6H6BrN3. It is a derivative of picoline, which is a type of heterocyclic compound. This particular compound is classified as an aminopyridine, and it contains both a bromine and an amino group. It is commonly used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Its chemical properties and reactivity make it useful in a variety of chemical reactions and processes. Additionally, it is important to handle this compound with care, as it may have hazardous properties that should be taken into consideration in its handling and use.

InChI:InChI=1/C6H7BrN2/c1-4-2-6(7)9-3-5(4)8/h2-3H,8H2,1H3

Upstream product

• 23056-47-5 2-bromo-4-methyl-5-nitropyridine 

Downstream Products

• 929617-35-6 5-bromo-1H-pyrazolo[3,4m-c]pyridine 
• 753921-02-7 6-(4-fluorophenoxy)-4-methylpyridin-3-amine 
• 307309-26-8 6-(2-fluorophenoxy)-4-methylpyridin-3-amine 

Relevant articles and documents

Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists

Design and synthesis of a novel class of 1H-pyrazolo[3,4-c]pyridine GPR119 receptor agonists are described. Lead compound 4 was identified through the ligand-based drug design approach. Modification of the left-hand aryl group (R1) and right-ha

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.